Dublin, June 25, 2019 (GLOBE NEWSWIRE) -- The "Global Benign Prostatic Hyperplasia Market: Growth, Trends, and Forecasts (2019-2024)" report has been added to ResearchAndMarkets.com's offering.

Benign prostatic hyperplasia (BPH) is most common among the aging men population, primarily driving this market.

Benign prostatic hyperplasia is being accepted as a growing health problem of elderly men. With the rising number of elderly males in the population, the degree of the problem is projected to rise multifold over the next few years. The advancements in early diagnosis of the disease and geriatric population are driving the demand for the benign prostatic hyperplasia market.

Key Market Trends

Alpha-Blockers Expected to Hold the Largest Share

Alpha-blockers help in relaxing the muscle of the prostate and the bladder neck, which allow urine to flow easier. Alpha-blockers work quickly and are usually the first line of treatment for men with mild to moderate symptoms.

For instance, 1 blockers are recommended in the Clinical Guidelines for BPH in Japan as first-line drug therapy for lower urinary tract symptoms (LUTS) associated with BPH. Moreover, for people with high blood pressure and BPH, alpha-blockers are ideal treatment line for both the conditions. Owing to these factors, alpha-blockers accounted for the largest market share in the global benign prostatic hyperplasia market.

North America Holds the Largest Market Share

North America dominates the market owing to the high prevalence of BPH and other associated lower urinary tract symptoms. Several studies in past one era have reported a significant percentage of men in the US, aged between 45 and 80 years suffer from some type of lower urinary tract symptoms and most have some form of BPH symptoms.

In addition, several hospitals across the US, and Canada have collaboration with the non-profit organization and companies such as GlaxoSmithKline in some of the projects to raise awareness and adequate resources for the treatment of urological disorders. Also, the rising geriatric population is bolstering the growth of the market. Thus, North America is a very lucrative market for the companies contributing to a large share of this market.

Competitive Landscape

The Benign Prostatic Hyperplasia Market market consists of several major players. The companies implement certain strategic initiatives such as a merger, new product launch, acquisition and partnerships that help them in strengthening their market position.

Topics Covered

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Geriatric Population
4.2.2 Growing Technological Advancements in Personalized Medicines
4.2.3 Rising Awareness Through Campaigns
4.3 Market Restraints
4.3.1 Rising Preference Towards Minimally Invasive Surgeries
4.3.2 Non-adherence of Patients to Pharmacological Therapy
4.4 Porter's Five Force Analysis

5 MARKET SEGMENTATION
5.1 By Drug Type
5.1.1 Alpha-Blockers
5.1.2 5- Alpha-Reductase Inhibitors (5-Aris)
5.1.3 Alpha-Adrenergic Blockers
5.1.4 Phosphodiesterase-5 Enzyme Inhibitors
5.1.5 Others
5.2 By Distribution Channel
5.2.1 Hospital Pharmacies
5.2.2 Retail Pharmacies
5.2.3 Online Pharmacies
5.3 Geography
5.3.1 North America
5.3.2 Europe
5.3.3 Asia-Pacific
5.3.4 Middle East & Africa
5.3.5 South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Allergan PLC
6.1.2 Astellas Pharma Inc.
6.1.3 Boehringer Ingelheim
6.1.4 Eli Lilly and Company
6.1.5 GlaxoSmithKline PLC
6.1.6 Nymox Pharmaceutical Corporation
6.1.7 Pfizer Inc.
6.1.8 Sanofi
6.1.9 Sophiris Bio Corp.
6.1.10 Teva Pharmaceutical Industries Limited

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/wg2b6p

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Prostate Cancer Drugs 

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.